CN103936627A

CN103936627A - Anti-HCV drug Boceprevir intermediate VII, preparation method and application thereof

Info

Publication number: CN103936627A
Application number: CN201310019928.XA
Authority: CN
Inventors: 姚旻; 袁哲东; 杨玉雷; 张浩宇
Original assignee: Shanghai Institute of Pharmaceutical Industry
Current assignee: Shanghai Institute of Pharmaceutical Industry; Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date: 2013-01-18
Filing date: 2013-01-18
Publication date: 2014-07-23
Anticipated expiration: 2033-01-18
Also published as: CN103936627B

Abstract

The present invention relates to the technical field of a method for preparation of an anti-HCV drug Boceprevir. The present invention provides compounds VII (C) of a formula as follows. The preparation of the compounds is simple and of high yield. The compounds can be used for synthesis of the anti-HCV drug Boceprevir. The present invention provides new implication and approach for the synthesis of the anti-HCV drug Boceprevir. Furthermore, a UV chromophore of the compounds makes the compounds more convenient to detect than compounds prepared by aconventional synthetic method, and introduction of a benzyl group to a hydroxyl group avoids side reactions during a condensation step due to the nucleophilicity of the hydroxyl group. There are certain advantages compared to an existing synthetic method.

Description

Intermediate VII of anti-the third liver medicine Boceprevir and its preparation method and application

Technical field

The present invention relates to the preparation method's technical field for anti-the third liver medicine Boceprevir.

Background technology

In global range, the infection rate of hepatitis C virus (hepatitis C virus, HCV) is about 3%, and the total number of persons of infection is about 200,000,000.Because the high infection rate of HCV also can cause potential complication as serious in liver cirrhosis, liver cancer etc., thereby HCV is a serious threat of human life's health.According to Simmonds naming system, it is I-VI that HCV can be divided into 6 oligogene types, various several hypotypes (as Ia, Ib, IIa, IIb, IIIa, IIIb etc.) that can be divided into again.HCV the infected of China approximately 4,000 ten thousand, and wherein 69% is I type infection (taking Ib type as main).The method for the treatment of chronic hepatitis C is mainly polyoxyethylene glycol Interferon, rabbit (PEG-IFN α) and ribavirin (RBV) drug combination at present, this kind of therapy patient of approximately 50% in HCV I type patient can not produce lasting virological response, and there is untoward reaction, thereby need the effective medicine of exploitation badly.Due to this needs, anti-HCV new drug development is very active, has at present more than 50 planting anti-HCV drug candidate or grantedly carrying out clinical trial.In these medicines, Victrelis (boceprevir) is treated adult's chronic hepatitis C on May 13rd, 2011 by U.S. FDA approval and polyoxyethylene glycol Interferon, rabbit and ribavirin coupling.

Boceprevir(structure is as above) be the chronic hepatitis C curative by the exploitation of Schering Plough company of the U.S., it is a kind of orally active HCV NS3 proteinase inhibitor, that the high NS3 of a kind of tool is suppressed to amino-acid residue on active 11 peptides carries out systemic brachymemma and modification and the micromolecular inhibitor found, can catch the Serine of NS3 reactive site, on its keto-amide carbonyl carbon therewith Serine in conjunction with forming covalency adducts, thereby cause NS3 inactivation.A research that is published in " New England Journal of Medicine " shows, for untreated chronic hcv genotype I type infected patient of the past, on polyoxyethylene glycol Interferon, rabbit-ribavirin standard care basis, add with Boceprevir, compared with simple standard care, can significantly increase the virological response rate that continues.

The synthesis strategy of Boceprevir mainly contains two kinds, patent WO02/08244A2 and J.Med.Chem.2006, and 49,6074-6086 has reported that three fragments are once hydrolyzed last oxidation pendant hydroxyl group and obtain the synthesis strategy of Boceprevir through twice condensation.Specific as follows:

Patent WO2008/079216 has reported the initial oxidation pendant hydroxyl group synthesis strategy of the Boceprevir of condensation again, specific as follows:

The patent that other are relevant or document are all the optimize and improves (specifically can be referring to US2004/018914, US2006/043950, US2007/025804 etc.) that carry out on the basis of above two kinds of synthesis strategies.But all there is a same problem in existing synthetic method: owing to all not existing obvious chromophoric group event reaction detection and intermediate control comparatively to bother in the structure of each intermediate.In a tactful condensation step, there is exposed hydroxyl in addition, will inevitably cause side reaction occur, in the process of actually operating also just so.The present inventor replaces by introducing in a certain intermediate or unsubstituted benzyl has successfully solved the problem of detection difficult and condensation step side reaction, consider the importance of hepatitis C virus (" HCV ") proteinase inhibitor, the intermediate of novel this inhibitor of preparation is interesting all the time simultaneously.

Summary of the invention

Object of the present invention is exactly to solve the problem existing in above-mentioned existing synthetic Boceprevir method, and a kind of new midbody compound is provided, preparation Boceprevir or this compounds that can simple and effective.

For reaching above-mentioned purpose, the technical scheme that the present invention takes is as follows:

Following general formula compound C:

R is the optional position substituting group of phenyl ring, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.

Above-mentioned new general formula compound C, can be for the preparation of hepatitis C (HCV) the proteinase inhibitor Boceprevir with following structure

The compound of formula C can make Boceprevir by two kinds of reaction paths shown in below:

Method one:

A), in organic solvent, under alkali effect, make following formula: compound C hydrolysis obtain Compound D

B), in organic solvent, under alkali existence condition, after following formula: compound D reacts with Vinyl chloroformate, directly react and obtain with strong aqua

C) compd E is in organic solvent, and under acidic conditions, deprotection base obtains

D), in organic solvent, under alkali and condensing agent existence condition, make following formula: compound G-1 and compound F 17-hydroxy-corticosterone condensation obtain formula 1

E) compound 1 hydro-reduction is obtained to compound 2, be then oxidized and obtain ultimate aim product B oceprevir

Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.

Method by formula 2 compound preparation formula (3) compd B oceprevir can be referring to patent US2006/043950, WO02/08244A2, J.Med.Chem.2006,49,6074-6086, US8188137B2.

According to the preferred embodiment of the present invention, step a) hydrolysis reaction, available alkali comprises potassium hydroxide, sodium hydroxide, lithium hydroxide, preferably sodium hydroxide and lithium hydroxide, more preferably lithium hydroxide.With respect to Compound C, the consumption of alkali can be 1 molar equivalent to 10 molar equivalent, preferably 1 molar equivalent to 5 molar equivalent, and more preferably 1 molar equivalent to 4 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc.; Protonic solvent, such as methyl alcohol, ethanol, water etc. or its suitable mixture.Preferred solvent is mixed solvent, more preferably tetrahydrofuran (THF)/methanol mixed solvent.This reaction can be at 0 DEG C～60 DEG C, preferably 0～40 DEG C, carry out approximately 4 hours or until react completely at the temperature of more preferably 10 DEG C～25 DEG C.

According to the preferred embodiment of the present invention, step b) can with alkali comprise triethylamine, N, N--diisopropylethylamine, pyridine, N-methylmorpholine, lithium hydroxide, sodium hydroxide, potassium hydroxide, preferably triethylamine, N, N--diisopropylethylamine and N--methylmorpholine, more preferably triethylamine.With respect to Compound D, the consumption of alkali is recommended as 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2.5 molar equivalent uses.With respect to Compound D, the consumption of Vinyl chloroformate can be extremely approximately 5 molar equivalents of 1 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2.5 molar equivalent uses.With respect to Compound D, strong aqua consumption can be 1 molar equivalent to 8 molar equivalent, preferably 1 molar equivalent to 5 molar equivalent, and more preferably 1 molar equivalent to 3 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably tetrahydrofuran (THF).Reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, carry out approximately 2 hours or until react completely at the temperature of more preferably 0 DEG C～25 DEG C.

According to the preferred embodiment of the present invention, step c) can with acid comprise hydrochloric acid, sulfuric acid, trifluoroacetic acid, preferably hydrochloric acid.With respect to compd E, sour that consumption can be at 1 molar equivalent to 20 molar equivalent, preferably 1 molar equivalent to 10 molar equivalent, more preferably 1 molar equivalent to 5 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably dioxane.Reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, more preferably at the temperature of 0～25 DEG C, carry out approximately 1 hour or until react completely.

According to the preferred embodiment of the present invention, alkali can be selected from triethylamine, pyridine, N-methylmorpholine, DIPEA, DMAP described in step d).Preferably N-methylmorpholine and DIPEA.With respect to compound F 17-hydroxy-corticosterone, alkali conventionally can 2 molar equivalent to 8 molar equivalents, preferably 2 molar equivalent to 5 molar equivalents, and more preferably 2 molar equivalent to 4 molar equivalents use.

According to the preferred embodiment of the present invention, condensing agent described in step d) can be selected from 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride (EDCI), benzotriazole-1-base oxygen base three (dimethylamino) phosphorus hexafluorophosphate (BOP), phosphofluoric acid benzotriazole-1-base-oxygen base tripyrrole alkyl (PyBOP), N, N'-carbonyl dimidazoles (CDI), 2-(7-azo benzotriazole)-N, N, N', N'-tetramethyl-urea phosphofluoric acid ester (HATU), 2-(7-azo benzotriazole)-tetramethyl-urea phosphofluoric acid ester (HATU), >=99.5% (HPLC) (HBTU), N, N'-dicyclohexylcarbodiimide (DCC) etc., preferably EDCI, BOP, PyBOP, HATU, more preferably EDCI and HATU.With respect to compound F 17-hydroxy-corticosterone, condensing agent conventionally can approximately 1 molar equivalent to approximately 5 molar equivalents, preferably 1 molar equivalent to 3 molar equivalent, more preferably from about 1 molar equivalent to 2 molar equivalent uses.

According to the preferred embodiment of the present invention, step d) can also add additive, described additive can be 1-hydroxyl-7-azo benzotriazole (HOAT), I-hydroxybenzotriazole (HOBT), >=99% (HPLC) etc.With respect to compound F 17-hydroxy-corticosterone, additive conventionally can approximately 0 molar equivalent to approximately 5 molar equivalents, preferably 1 molar equivalent to 3 molar equivalent, more preferably from about 1 molar equivalent to 2 molar equivalent uses.With respect to compound F 17-hydroxy-corticosterone, compound G-1 consumption approximately 1 molar equivalent to 2 molar equivalent, preferably 1 molar equivalent to 1.5 molar equivalent, more preferably from about 1 molar equivalent to 1.2 molar equivalent uses.

According to the preferred embodiment of the present invention, step d) can with solvent comprise ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; Esters solvent, such as ethyl acetate etc., and other solvents, such as DMF, DMSO, acetonitrile etc. or its suitable mixture.Preferred solvent is other solvents, more preferably DMF and acetonitrile.

According to the preferred embodiment of the present invention, step d) reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, carry out approximately 24 hours or until react completely at the temperature of more preferably 0 DEG C～25 DEG C.

Method two:

B), in organic solvent, under alkali existence condition, Compound D is directly reacted and is obtained with strong aqua after reacting with Vinyl chloroformate

C) compd E is in organic solvent, and under acidic conditions, deprotection base obtains:

D), in organic solvent, under alkali and condensing agent existence condition, make compound F 17-hydroxy-corticosterone and compound G-2 condensation obtain compound F 17-hydroxy-corticosterone-1

E) in organic solvent, under acidic conditions, make compound F 17-hydroxy-corticosterone-1 deprotection base, obtain compound F 17-hydroxy-corticosterone-2

F), in organic solvent, under alkali and condensing agent existence condition, make compound F 17-hydroxy-corticosterone-2 and compound G-3 condensation obtain formula 1 compound

G) compound 1 hydro-reduction is obtained to compound 2, be then oxidized and obtain ultimate aim product B oceprevir

Method by formula (2) compound preparation formula (3) compound can be referring to patent US2006/043950, WO02/08244A2 .J.Med.Chem.2006,49,6074-6086 US8188137B2.

According to the preferred embodiment of the present invention, step b) can with alkali comprise triethylamine, DIPEA, pyridine, N-methylmorpholine, lithium hydroxide, sodium hydroxide, potassium hydroxide, preferably triethylamine, N, N-diisopropylethylamine and N-methylmorpholine, more preferably triethylamine.With respect to Compound D, the consumption of alkali is recommended as 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2.5 molar equivalent uses.With respect to Compound D, the consumption of Vinyl chloroformate can be extremely approximately 5 molar equivalents of 1 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2.5 molar equivalent uses.With respect to Compound D, strong aqua consumption can be 1 molar equivalent to 8 molar equivalent, preferably 1 molar equivalent to 5 molar equivalent, and more preferably 1 molar equivalent to 3 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably tetrahydrofuran (THF).Reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, carry out approximately 2 hours or until react completely at the temperature of more preferably 0 DEG C～25 DEG C.

Step c) can with acid comprise hydrochloric acid, sulfuric acid, trifluoroacetic acid, preferably hydrochloric acid.With respect to compd E, sour that consumption can be at 1 molar equivalent to 20 molar equivalent, preferably 1 molar equivalent to 10 molar equivalent, more preferably 1 molar equivalent to 5 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably dioxane.Reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, more preferably at the temperature of 0～25 DEG C, carry out approximately 1 hour or until react completely.

Step d) can with alkali comprise triethylamine, DIPEA, pyridine and N-methylmorpholine, preferably N-methylmorpholine and DIPEA.With respect to compound F 17-hydroxy-corticosterone, the consumption of alkali can be 2 molar equivalent to 8 molar equivalents, preferably 2 molar equivalent to 5 molar equivalents, and more preferably 2 molar equivalent to 4 molar equivalents use.Available condensing agent comprises EDCI, BOP, PyBOP, CDI, HATU, HBTU and DCC, preferably EDCI, BOP, PyBOP and HATU, more preferably EDCI and HATU.With respect to compound F 17-hydroxy-corticosterone, condensing agent consumption can be 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.Step a) also can add additive, and additive comprises HOBT and HOAT etc.With respect to compound F 17-hydroxy-corticosterone, additive amount can be 0 to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably from about 1 molar equivalent to 2 molar equivalent uses.With respect to compound F 17-hydroxy-corticosterone, compound G-2 conventionally can approximately 1 molar equivalent to approximately 2 molar equivalents, preferably 1 molar equivalent to 1.5 molar equivalent, more preferably 1 molar equivalent to 1.2 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; Esters solvent, such as ethyl acetate etc., and other solvents, such as DMF, DMSO, acetonitrile etc. or its suitable mixture.Preferred solvent is other solvents, more preferably DMF and acetonitrile.Reaction can, at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, be carried out at the temperature of more preferably 0 DEG C～25 DEG C approximately 24 hours or until react completely.

The acid that step e) is used comprises hydrochloric acid, sulfuric acid, trifluoroacetic acid, preferably hydrochloric acid.With respect to compound F 17-hydroxy-corticosterone-1, sour that consumption can be 1 molar equivalent to 20 molar equivalent, preferably 1 molar equivalent to 10 molar equivalent, more preferably 1 molar equivalent to 5 molar equivalent uses.Available solvent comprises ether solvent, as ether, THF, methyl tertiary butyl ether, THP, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably dioxane.Reaction can, at-25 DEG C～50 DEG C, preferably-10 DEG C～25 DEG C, be carried out at the temperature of more preferably 0 DEG C～25 DEG C approximately 1 hour or until react completely.

Step f) can with alkali comprise triethylamine, DIPEA, pyridine, N-methylmorpholine, preferably N-methylmorpholine and DIPEA.With respect to compound F 17-hydroxy-corticosterone-2, the consumption of alkali can be at 2 molar equivalent to 8 molar equivalents, preferably 2 molar equivalent to 5 molar equivalents, and more preferably 2 molar equivalent to 4 molar equivalents use.Available condensing agent comprises EDCI, BOP, PyBOP, CDI, HATU, HBTU, DCC, preferably EDCI, BOP, PyBOP, HATU, more preferably EDCI and HATU.With respect to compound F 17-hydroxy-corticosterone-2, the consumption of condensing agent can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.For promoting reaction to carry out, can also add additive, available additive comprises HOBT, HOAT.With respect to compound F 17-hydroxy-corticosterone-1, the consumption of additive is at 0 to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.With respect to compound F 17-hydroxy-corticosterone-2, the consumption of compound G-3 can be at 1 molar equivalent to 2 molar equivalent, preferably 1 molar equivalent to 1.5 molar equivalent, and more preferably 1 molar equivalent to 1.2 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans, dioxane etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; Esters solvent, such as ethyl acetate etc., and other solvents, such as DMF, DMSO, acetonitrile etc. or its suitable mixture.Preferred solvent is other solvents, more preferably DMF and acetonitrile.

New compound C of the present invention can, by the compd B of following formula, in organic solvent, under catalyst action, through hydrazine hydrate effect obtain after reacting with tert-Butyl dicarbonate again:

Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.Preferably R is in contraposition; Preferably R is the alkyl of hydrogen or C1-C3, more preferably hydrogen.

Available catalyzer can be DMAP, triethylamine, butyllithium, sodium hydroxide etc., preferably DMAP and triethylamine, more preferably DMAP.With respect to compd B, the consumption of catalyzer conventionally can be at 0.2 molar equivalent to 3 molar equivalent, preferably 0.2 molar equivalent to 1 molar equivalent, and more preferably 0.2 molar equivalent to 0.5 molar equivalent uses.With respect to compd B, the consumption of tert-Butyl dicarbonate conventionally can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 2 molar equivalent uses.With respect to compd B, the consumption of hydrazine hydrate conventionally can be at 2 molar equivalent to 10 molar equivalents, preferably 2 molar equivalent to 5 molar equivalents, and more preferably 2 molar equivalent to 4 molar equivalents use.With tert-Butyl dicarbonate be used as the used time can solvent comprise ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably tetrahydrofuran (THF).When hydrazinolysis can with solvent comprise ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Halohydrocarbon, for example, methylene dichloride, chloroform, tetracol phenixin, ethylene dichloride etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; Protonic solvent, such as methyl alcohol, ethanol, water etc. or its suitable mixture.Preferred solvent is mixed solvent, more preferably the mixed solvent of tetrahydrofuran (THF)/methyl alcohol.Compd B can be under 25 DEG C～reflux temperature with reacting of tert-Butyl dicarbonate, and preferably 50 DEG C～reflux temperature, more preferably carries out under reflux temperature, approximately 8 hours or until react completely; Hydrazinolysis reaction can be at-25 DEG C～50 DEG C, preferably-10 DEG C～approximately 25 DEG C, carry out approximately 4 hours or until react completely at the temperature of more preferably 10 DEG C～25 DEG C.

Compd B can, by the compd A of following formula, in organic solvent, under alkali existence condition, react and obtain with replacement or unsubstituted benzyl halide:

In above-mentioned replacement or unsubstituted benzyl halide, X can be chlorine or bromine, and preferably X is bromine; R can be hydrogen, C1-C6 alkyl or C1-C6 alkoxyl group, and preferably R is hydrogen or C1-C3 alkyl; R can be at phenyl ring the position of substitution not arbitrarily, and preferably R is in contraposition.With respect to compd A, the consumption of replacement or unsubstituted benzyl halide conventionally can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 1.3 molar equivalent uses.Available alkali comprises potassium tert.-butoxide, sodium hydride, potassium hydride KH, two (trimethyl silicon based) Lithamide, two (trimethyl silicon based) sodium amide, two (trimethyl silicon based) potassium amide, lithium diisopropylamine, butyllithium, preferably potassium tert.-butoxide, sodium hydride, two (trimethyl silicon based) Lithamide, more preferably sodium hydride.With respect to compd A, alkali conventionally can be at 1 molar equivalent to 5 molar equivalent, preferably 1 molar equivalent to 3 molar equivalent, and more preferably 1 molar equivalent to 1.5 molar equivalent uses.Available solvent comprises ether solvent, as ether, tetrahydrofuran (THF), methyl tertiary butyl ether, tetrahydropyrans etc.; Aromatic solvent, such as toluene, benzene, dimethylbenzene, Three methyl Benzene, chlorobenzene etc.; And esters solvent, such as ethyl acetate etc. or its suitable mixture.Preferred solvent is ether solvent, more preferably tetrahydrofuran (THF).Reaction can be at-25 DEG C～25 DEG C, preferably-10 DEG C～10 DEG C, carry out approximately 2 hours or until react completely at the temperature of more preferably-5 DEG C～0 DEG C.

Compd A of the present invention can be prepared by means known in the art, in detail referring to Chinese patent application 201210200429.6.

The invention provides a kind of new compound C, the preparation of this compounds, operation is easy, and yield is higher.Use this compounds to can be used for the synthetic of anti-the third liver medicine Boceprevir, this is that anti-the third liver medicine Boceprevir synthetic provides new thinking and method.And convenient with the more original synthetic method detection of ultraviolet chromophoric group in such compound molecule, on hydroxyl, the side reaction causing because of hydroxyl nucleophilicity in condensation step has been avoided in the introducing of benzyl in addition, has certain advantage compared with existing synthetic method.

Embodiment

The reactions steps below relating to for the preferred embodiment of the present invention, outside indicating, chemical and solvent that the present invention is all obtain from commercial channel, use front without being further purified.

Embodiment 1-9:R is the preparation of formula 1 compound of hydrogen

Embodiment 1: the preparation of compd B

Compd A (5g, 20.6mmol) is dissolved in 40ml DMF and is added in there-necked flask, is cooled to-5 DEG C, add NaH (60% in batches, 1.1g, 26.8mmol), stir 1h, at-5 DEG C, drip 40ml BnBr (4.2g, DMF solution 24.7mmo), dropwise at this temperature and stir 2h, add frozen water cancellation reaction, extract with ethyl acetate, on a small quantity repeatedly, merge organic phase, desolventize and obtain yellow oil with anhydrous sodium sulfate drying after saturated common salt water washing steaming, it is white solid that column chromatography obtains 6.2g compd B, yield 90.4%, m/z (MH+) 334.16, 1H NMR (400MHz, CDCl3) δ 1.31 (t, 3H), 1.41-1.57 (m, 4H), 1.64-1.74 (m, 2H), 1.77 (s, 3H), 1.96-2.06 (m, 2H), 2.25-2.29 (m, 1H), 3.95 (d, 1H), 4.19-4.25 (m, 3H), 4.28 (d, 1H), 4.81 (d, 1H), 5.63 (d, 1H), 7.30-7.35 (m, 5H).

Embodiment 2: the preparation of Compound C

Compd B (5g, 15mmol), DMAP (0.37g, 3mmol) are dissolved in 60ml THF, add (Boc) ₂o (6.88ml, 30mmol), be warming up to backflow, reflux and be down to room temperature after about 8h and add 60ml methyl alcohol and hydrazine hydrate (3g, 60mmol) after stirring 4h, add the dilution of 200ml methylene dichloride, reaction solution is successively with 1N HCl, copper-bath, saturated sodium bicarbonate solution and saturated common salt water washing, after anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 4.4g Compound C, yield 75.0%, m/z (MNa+) 414.06, 1H NMR (400MHz, CDCl3) δ 1.32 (t, 3H), 1.44 (s, 9H), 1.48-1.68 (m, 4H), 1.78-1.87 (m, 2H), 2.02-2.11 (m, 2H), 2.33-2.37 (m, 1H), 3.98 (m, 1H), 4.20-4.32 (m, 3H), 4.43 (d, 1H), 4.65 (d, 1H), 4.81 (d, 1H), 7.30-7.37 (m, 5H).

Embodiment 3: the preparation of Compound D

Compound C (2g, 5mmol) be dissolved in 20ml MeOH/THF (v/v1:1) solution, add 20ml1M LiOH solution, stirring at room temperature 4h, adds 1M potassium hydrogen sulfate solution to regulate PH to 2, with dichloromethane extraction, merge organic phase, organic phase is used saturated sodium bicarbonate and saturated common salt water washing successively, and after anhydrous sodium sulfate drying steaming desolventize, obtaining Compound D is white solid 1.91g, yield 100%, m/z (MNa+) 386.13.

Embodiment 4: the preparation of compd E

Compound D (1.91g, 5mmol) be dissolved in the anhydrous THF of 30ml and be cooled to 0 DEG C, add triethylamine (1.9ml, 12.5mmol), add Vinyl chloroformate (1.2ml, 11mmol), stir 15min at 0 DEG C after, add 30% ammoniacal liquor (2ml, 13.5mmol) and at 0 DEG C stir 30min, after adding ethyl acetate 50ml, stir 20min, suction filtration is removed solid, filtrate is successively with 1M sal enixum, saturated sodium bicarbonate and saturated common salt solution washing, anhydrous sodium sulfate drying, after desolventizing, steaming obtains white solid, it is a white solid that column chromatography obtains 3.30g compd E, yield 71.2%.m/z(MNa+)385.16,1H?NMR(400MHz,CDCl3)δ1.44(s,9H),1.61-1.70(m,4H),1.76-1.90(m,2H),2.03-2.10(m,2H),2.34-2.40(m,1H),3.80-3.98(m,1H),4.47(s,1H),4.60-4.67(m,2H),5.50(s,1H),6.46(s,1H),7.28-7.41(m,5H)。

Embodiment 5: the preparation of compound F 17-hydroxy-corticosterone

By compd E (422mg, 1.12mmol) be dissolved in 5ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 350mg compound F 17-hydroxy-corticosterone for 4 times is a white solid, yield 100%, m/z (MH+) 263.13.

Embodiment 6: the preparation of formula 1 compound

G-1 (136mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (117mg, 0.37mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-1, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 177mg formula 1 compound, it is a white solid, yield 78.0%, m/z (MNa+) 634.34, 1H NMR (400MHz, DMSO-d) δ 0.89 (m, 9H), 0.82-1.00 (m, 6H), 1.17 (s, 9H), 1.26 (m, 1H), 1.43 (m, 1H), 1.65-1.74 (m, 4H), 1.78-1.94 (m, 2H), 2.01-2.08 (m, 2H), 2.36-2.40 (m, 1H), 3.74-3.76 (m, 2H), 3.92-3.97 (m, 1H), 4.11 (d, 1H), 4.26 (s, 1H), 4.47 (s, 1H), 4.60-4.67 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 7.28-7.46 (m, 5H), 7.76-8.04 (br, 2H), 8.20-8.30 (s, 1H).

Embodiment 7: the preparation of compound F 17-hydroxy-corticosterone-1

G-2 (94mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, adds NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.37mmol) is added in 8ml DMF, this solution is added in the reaction soln of G-2, and 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 146mg compound F 17-hydroxy-corticosterone-1, it is a white solid, yield 79.2%, m/z (MNa+) 522.30, 1H NMR (400MHz, DMSO-d) δ 0.92-1.03 (m, 6H), 1.23-1.26 (m, 1H), 1.44 (s, 9H), 1.46-1.50 (m, 1H), 1.64-1.74 (m, 4H), 1.75-1.92 (m, 2H), 2.03-2.08 (m, 2H), 2.38-2.44 (m, 1H), 3.54-3.72 (m, 2H), 3.91-3.97 (m, 1H), 4.13 (d, 1H), 4.49 (s, 1H), 4.60-4.69 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 7.25-7.49 (m, 5H).

Embodiment 8: compound F 17-hydroxy-corticosterone-2 synthetic

By compound F 17-hydroxy-corticosterone-1 (140mg, 0.28mmol) be dissolved in 3ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 120mg compound F 17-hydroxy-corticosterone-2 for 4 times is a white solid, yield 100%, m/z (MH+) 400.30.

Embodiment 9: the preparation of formula 1 compound

G-3 (78mg, 0.34mmol), HATU (128mg, 0.34mmol) are dissolved in 8ml DMF, and ice-water bath is cooling, add DIEA (0.18mml, 1.00mmol), stir 30min; In compound F 17-hydroxy-corticosterone-2 (120mg, 0.28mmol), be added in 8ml DMF, this solution be added in the reaction soln of G-2,0 DEG C of stirring is spent the night; In reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, and column chromatography obtains 118mg formula 1 compound, be a white solid, yield 68.7%.

Embodiment 10-18:R is methyl and the R preparation at formula 1 compound of contraposition

Embodiment 10: the preparation of compd B

Compd A (2g, 8.23mmol) be dissolved in 10ml DMF and be added in there-necked flask, be cooled to-5 DEG C, add NaH (60% in batches, 0.43g, 10.70mmol), stir 1h, at-5 DEG C, drip 10ml to methyl bromobenzyl (1.83g, DMF solution 9.88mmo), dropwise at this temperature and stir 2h, add frozen water cancellation reaction, extract with ethyl acetate, on a small quantity repeatedly, merge organic phase, with anhydrous sodium sulfate drying after saturated common salt water washing, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 2.4g compd B, yield 82.5%, 1H NMR (400MHz, CDCl3) δ 1.31 (t, 3H), 1.43-1.64 (m, 4H), 1.74-1.78 (m, 2H), 1.83 (s, 3H), 1.97-2.05 (m, 2H), 2.25-2.29 (m, 1H), 2.34 (s, 3H), 4.00 (d, 2H), 4.17-4.33 (m, 4H), 4.77 (d, 1H), 5.58 (d, 1H), 7.16 (d, 2H), 7.23 (d, 2H).

Embodiment 11: the preparation of Compound C

Compd B (1.8g, 5.19mmol), DMAP (0.13g, 1.04mmol) are dissolved in 20ml THF, add (Boc) ₂o (2.4ml, 10.38mmol), be warming up to backflow, reflux and be down to room temperature after about 8h and add 20ml methyl alcohol and hydrazine hydrate (1.04g, 20.76mmol) after stirring 4h, add the dilution of 100ml methylene dichloride, reaction solution is successively with 1N HCl, copper-bath, saturated sodium bicarbonate solution and saturated common salt water washing, after anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 1.34g Compound C, yield 63.7%, m/z (MNa+) 428.06, 1H NMR (400MHz, CDCl3) δ 1.32 (t, 3H), 1.43 (s, 9H), 1.50-1.67 (m, 4H), 1.76-1.91 (m, 2H), 2.00-2.10 (m, 2H), 2.30-2.33 (m, 1H), 2.35 (s, 3H), 3.94-3.98 (m, 1H), 4.00 (d, 1H), 4.17-4.38 (m, 3H), 4.64 (d, 1H), 4.79 (d, 1H), 7.17 (d, 2H), 7.27 (d, 2H).

Embodiment 12: the preparation of Compound D

Compound C (1.2g, 2.96mmol) is dissolved in 20ml MeOH/THF (v/v1:1) solution, adds 20ml1M LiOH solution, stirring at room temperature 4h, add 1M potassium hydrogen sulfate solution to regulate PH to 2, with dichloromethane extraction, merge organic phase, organic phase is used saturated sodium bicarbonate and saturated common salt water washing successively, anhydrous sodium sulfate drying steams and removes, and obtains Compound D 1.2g after solvent, is white solid, yield 100%, m/z (MNa+) 400.13.

Embodiment 13: the preparation of compd E

Compound D (1.2g, 3.19mmol) be dissolved in the anhydrous THF of 20ml and be cooled to 0 DEG C, add triethylamine (1.1ml, 7.98mmol), add Vinyl chloroformate (0.7ml, 7.02mmol), stir 15min at 0 DEG C after, add 30% ammoniacal liquor (1ml, 8.61mmol) and at 0 DEG C stir 30min, after adding ethyl acetate 50ml, stir 20min, suction filtration is removed solid, filtrate is successively with 1M sal enixum, saturated sodium bicarbonate and saturated common salt solution washing, anhydrous sodium sulfate drying, after desolventizing, steaming obtains white solid, column chromatography obtains 831mg compd E, it is a white solid, yield 69.3%, m/z (MNa+) 399.16, 1H NMR (400MHz, CDCl3) δ 1.43 (s, 9H), 1.60-1.71 (m, 4H), 1.77-1.93 (m, 2H), 2.00-2.10 (m, 2H), 2.35 (s, 3H), 2.36-2.40 (m, 1H), 3.83-3.98 (m, 1H), 4.50 (s, 1H), 4.62-4.69 (m, 2H), 5.50 (s, 1H), 6.47 (s, 1H), 7.18 (d, 2H), 7.25 (d, 2H).

Embodiment 14: the preparation of compound F 17-hydroxy-corticosterone

By compd E (400mg, 1.06mmol) be dissolved in 5ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 330mg compound F 17-hydroxy-corticosterone for 4 times is a white solid, yield 100%, m/z (MH+) 277.13.

Embodiment 15: the preparation of compound 1

G-1 (136mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.38mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-1, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 173mg formula 1 compound, it is a white solid, yield 72.7%, m/z (MNa+) 648.34, 1H NMR (400MHz, DMSO-d) δ 0.88-0.92 (m, 9H), 0.81-1.02 (m, 6H), 1.18 (s, 9H), 1.27 (m, 1H), 1.45 (m, 1H), 1.68-1.75 (m, 4H), 1.81-1.94 (m, 2H), 2.03-2.09 (m, 2H), 2.33-2.41 (m, 1H), 2.35 (s, 3H), 3.75-3.77 (m, 2H), 3.92-3.97 (m, 1H), 4.13 (d, 1H), 4.25 (s, 1H), 4.44 (s, 1H), 4.61-4.67 (m, 2H), 5.48 (s, 1H), 6.42 (s, 1H), 7.17 (d, 2H), 7.23 (d, 2H), 7.77-8.04 (br, 2H), 8.20-8.28 (s, 1H).

Embodiment 16: the preparation of compound F 17-hydroxy-corticosterone-1

G-2 (94mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.38mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-2, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 139mg compound F 17-hydroxy-corticosterone-1, it is a white solid, yield 73.1%, m/z (MNa+) 536.30, 1H NMR (400MHz, DMSO-d) δ 0.90-1.03 (m, 6H), 1.22-1.26 (m, 1H), 1.44 (s, 9H), 1.48-1.51 (m, 1H), 1.62-1.71 (m, 4H), 1.75-1.92 (m, 2H), 2.03-2.08 (m, 2H), 2.34 (s, 3H), 2.37-2.44 (m, 1H), 3.54-3.70 (m, 2H), 3.90-3.97 (m, 1H), 4.13 (d, 1H), 4.52 (s, 1H), 4.60-4.69 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 7.18 (d, 2H), 7.23 (d, 2H).

Embodiment 17: compound F 17-hydroxy-corticosterone-2 synthetic

By compound F 17-hydroxy-corticosterone-1 (139mg, 0.27mmol) be dissolved in 3ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 120mg compound F 17-hydroxy-corticosterone-2 for 4 times is a white solid, yield 100%, m/z (MH+) 414.30.

Embodiment 18: the preparation of formula 1 compound

G-3 (78mg, 0.34mmol), HATU (128mg, 0.34mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add DIEA (0.18mml, 1.00mmol), stir 30min, compound F 17-hydroxy-corticosterone-2 (120mg, 0.27mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-3, 0 DEG C of stirring is spent the night, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 102mg formula 1 compound, it is a white solid, yield 60.2%.

Embodiment 19-27:R is methoxyl group and the R preparation at formula 1 compound of contraposition

Embodiment 19: the preparation of compd B

Compd A (4g, 16.46mmol) is dissolved in 10ml DMF and is added in there-necked flask, is cooled to-5 DEG C; After adding NaH (60%, 0.86g, 21.40mmol), stir 1h in batches; At-5 DEG C, drip the DMF solution of 10ml to methoxyl group benzyl chloride (3.08g, 19.75mmol), dropwise at this temperature and stir 2h; Add frozen water cancellation reaction, with ethyl acetate extraction, on a small quantity repeatedly, merge organic phase, desolventize and obtain yellow oil with anhydrous sodium sulfate drying steaming after saturated common salt water washing; It is white solid that column chromatography obtains 2.3g compd B, yield 37.9%, m/z (MH+) 364.16

Embodiment 20: the preparation of Compound C

Compd B (2.0g, 5.51mmol), DMAP (134mg, 1.10mmol) are dissolved in 20ml THF, add (Boc) ₂o (2.5ml, 11.02mmol), be warming up to backflow, reflux and be down to room temperature after about 8h and add 20ml methyl alcohol and hydrazine hydrate (1.10g, 22.04mmol) after stirring 4h, add the dilution of 100ml methylene dichloride, reaction solution is successively with 1N HCl, copper-bath, saturated sodium bicarbonate solution and saturated common salt water washing, after anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oil, it is white solid that column chromatography obtains 1.51g Compound C, yield 65.3%, (MNa+) 444.06.

Embodiment 21: the preparation of Compound D

Compound C (1g, 2.57mmol) be dissolved in 20ml MeOH/THF (v/v1:1) solution, add 20ml1MLiOH solution, stirring at room temperature 4h, adds 1M potassium hydrogen sulfate solution to regulate PH to 2, with dichloromethane extraction, merge organic phase, organic phase is used saturated sodium bicarbonate and saturated common salt water washing successively, and it is white solid that anhydrous sodium sulfate drying obtains Compound D 950mg after steaming and desolventizing, yield 100%, m/z (MNa+) 416.13.

Embodiment 22: the preparation of compd E

Compound D (900mg, 2.29mmol) be dissolved in the anhydrous THF of 20ml and be cooled to 0 DEG C, add triethylamine (0.8ml, 5.73mmol), add Vinyl chloroformate (0.5ml, 5.04mmol), stir 15min at 0 DEG C after, add 30% ammoniacal liquor (0.7ml, 8.61mmol) and at 0 DEG C stir 30min, after adding ethyl acetate 50ml, stir 20min, suction filtration is removed solid, filtrate is successively with 1M sal enixum, saturated sodium bicarbonate and saturated common salt solution washing, anhydrous sodium sulfate drying, after desolventizing, steaming obtains white solid, it is a white solid that column chromatography obtains 587mg compd E, yield 65.4%, m/z (MNa+) 415.16.

Embodiment 23: the preparation of compound F 17-hydroxy-corticosterone

By compd E (950mg, 2.42mmol) be dissolved in 5ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 795mg compound F 17-hydroxy-corticosterone for 4 times is a white solid, yield 100%, m/z (MH+) 293.13.

Embodiment 24: the preparation of compound 1

G-1 (136mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.37mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-1, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with dichloromethane extraction reaction solution, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 145mg formula 1 compound, it is a white solid, yield 61.3%, m/z (MNa+) 664.34, 1H NMR (400MHz, DMSO-d) δ 0.87-0.92 (m, 9H), 0.82-1.02 (m, 6H), 1.18 (s, 9H), 1.28 (m, 1H), 1.44 (m, 1H), 1.66-1.75 (m, 4H), 1.82-1.94 (m, 2H), 2.03-2.09 (m, 2H), 2.33-2.41 (m, 1H), 3.75-3.77 (m, 2H), 3.83 (s, 3H), 3.92-3.97 (m, 1H), 4.13 (d, 1H), 4.25 (s, 1H), 4.44 (s, 1H), 4.61-4.67 (m, 2H), 5.48 (s, 1H), 6.42 (s, 1H), 6.90 (d, 2H), 6.99 (d, 2H), 7.77-8.04 (br, 2H), 8.20-8.28 (s, 1H).

Embodiment 25: the preparation of compound F 17-hydroxy-corticosterone-1

G-2 (94mg, 0.37mmol), EDCI (105mg, 0.59mmol), HOBt (100mg, 0.59mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add NMM (0.23mml, 1.56mmol), stir 30min, compound F 17-hydroxy-corticosterone (120mg, 0.37mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-2, 0 DEG C is stirred 2 days, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 126mg compound F 17-hydroxy-corticosterone-1, it is a white solid, yield 64.6%, m/z (MNa+) 552.30, 1H NMR (400MHz, DMSO--d) δ 0.91-1.03 (m, 6H), 1.20-1.26 (m, 1H), 1.44 (s, 9H), 1.48-1.51 (m, 1H), 1.62-1.71 (m, 4H), 1.75-1.92 (m, 2H), 2.03-2.08 (m, 2H), 2.38-2.44 (m, 1H), 3.54-3.70 (m, 2H), 3.84 (s, 3H), 3.91-3.97 (m, 1H), 4.11 (d, 1H), 4.52 (s, 1H), 4.634.70 (m, 2H), 5.52 (s, 1H), 6.44 (s, 1H), 6.91 (d, 2H), 7.02 (d, 2H).

Embodiment 26: compound F 17-hydroxy-corticosterone-2 synthetic

By compound F 17-hydroxy-corticosterone-1 (120mg, 0.23mmol) be dissolved in 3ml4N HCl/dioxane and stir 1h, concentrated by adding 10ml methylene dichloride to continue after the volatile matter evaporate to dryness of above-mentioned reaction solution, repeating to obtain 105mg compound F 17-hydroxy-corticosterone-2 for 4 times is a white solid, yield 100%, m/z (MH+) 430.30.

Embodiment 27: the preparation of formula 1 compound

G-3 (30mg, 0.13mmol), HATU (50mg, 0.13mmol) be dissolved in 8ml DMF, ice-water bath is cooling, add DIEA (0.1ml, 0.57mmol), stir 30min, compound F 17-hydroxy-corticosterone-2 (50mg, 0.11mmol) be added in 8ml DMF, this solution is added in the reaction soln of G-2, 0 DEG C of stirring is spent the night, in reaction solution, add 50ml water, with ethyl acetate extractive reaction liquid, organic phase is successively with 1N hydrochloric acid and saturated sodium bicarbonate solution washing, again with saturated common salt water washing, anhydrous sodium sulfate drying, steaming desolventizes and obtains yellow oily matter, column chromatography obtains 40mg formula 1 compound, it is a white solid, yield 57.2%

Embodiment 28: formula 1 compound preparation formula 2 compounds taking R as hydrogen

By formula 1 compound (50mg, 0.08mmol) be dissolved in 20ml methyl alcohol, add the palladium carbon of 10mg10%, be placed on 40 DEG C, in the hydrogen atmosphere of 0.7MP, stir and spend the night, with diatomite filtering palladium carbon, after gained filtrate is concentrated, obtaining formula (2) compound 39mg, is a white solid, yield 92.3%, m/z (MNa+) 544.42, HPLC shows that purity is 91.2%.

Embodiment 5

Embodiment 29: taking R as methyl and R at formula 1 compound preparation formula 2 compounds of contraposition

By formula 1 compound (50mg, 0.08mmol) be dissolved in 20ml methyl alcohol, add the palladium carbon of 10mg10%, be placed on 40 DEG C, in the hydrogen atmosphere of 0.7MP, stir and spend the night, after concentrating with diatomite filtering palladium carbon gained filtrate, obtain formula (2) compound 37mg, it is a white solid, yield 89.5%, m/z (MNa+) 544.42, HPLC shows that purity is 90.3%.

Claims

1. following general formula compound C:

R is the optional position substituting group of phenyl ring, and R is hydrogen, alkyl or alkoxyl group.

2. general formula compound C as claimed in claim 1, is characterized in that: R is in contraposition.

3. general formula compound C as claimed in claim 1 or 2, is characterized in that: R is the alkyl of hydrogen or C1-C3.

4. general formula compound C as claimed in claim 3, is characterized in that: R is hydrogen.

5. the application of any described Compound C of claim 1-4, is characterized in that: for the preparation of the compound 2 of following formula

6. the application of Compound C as claimed in claim 5, is characterized in that: the preparation process of compound 2 is as follows:

E) by compound 1 hydro-reduction

R is the optional position substituting group of phenyl ring, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.

7. the application of Compound C as claimed in claim 5, is characterized in that: the preparation process of compound 2 is as follows:

C), in organic solvent, under alkali and condensing agent existence condition, make compound F 17-hydroxy-corticosterone and compound G-2 condensation obtain compound F 17-hydroxy-corticosterone-1

D) in organic solvent, under acidic conditions, make compound F 17-hydroxy-corticosterone-1 deprotection base, obtain compound F 17-hydroxy-corticosterone-2

E), in organic solvent, under alkali and condensing agent existence condition, make compound F 17-hydroxy-corticosterone-2 and compound G-3 condensation obtain formula 1 compound

F) compound 1 hydro-reduction is obtained to compound 2

Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group, and A is acid group.

8. the application of Compound C as claimed in claim 6, is characterized in that: described in step d), alkali is selected from triethylamine, pyridine, N-methylmorpholine, DIPEA, DMAP.

9. the application of Compound C as claimed in claim 8, is characterized in that: described in step d), alkali is N-methylmorpholine or DIPEA.

10. the application of Compound C as claimed in claim 6, is characterized in that: the condensing agent described in step d) is selected from EDCI, BOP, PyBOP, CDI, HATU and HBTU and DCC.

11. application of Compound C as claimed in claim 10, is characterized in that: the condensing agent described in step d) is EDCI, BOP, PyBOP or HATU.

12. application of Compound C as claimed in claim 6, is characterized in that: step d) adds additive HOBt or HOAT.

13. application of Compound C as claimed in claim 6, is characterized in that: the said acid of step c) comprises hydrochloric acid, sulfuric acid and trifluoroacetic acid.

14. application of Compound C as claimed in claim 6, is characterized in that: the said alkali of step b) comprises triethylamine, DIPEA, pyridine, N-methylmorpholine, lithium hydroxide, sodium hydroxide and potassium hydroxide.

15. application of Compound C as claimed in claim 6, is characterized in that: the strong aqua that the said strong aqua mass concentration of step b) is 28-35%.

16. application of Compound C as claimed in claim 6, is characterized in that: the said alkali of step a) comprises potassium hydroxide, sodium hydroxide and lithium hydroxide.

17. application of Compound C as claimed in claim 7, is characterized in that: the said alkali of step a) comprises potassium hydroxide, sodium hydroxide and lithium hydroxide.

18. application of Compound C as claimed in claim 7, is characterized in that: the said acid of step c) comprises hydrochloric acid, sulfuric acid and trifluoroacetic acid.

19. application of Compound C as claimed in claim 7, is characterized in that: the alkali that step d) is used comprises triethylamine, DIPEA, pyridine and N-methylmorpholine.

20. application of Compound C as claimed in claim 7, is characterized in that: the condensing agent that step d) is used comprises EDCI, BOP, PyBOP, CDI, HATU, HBTU and DCC.

21. application of Compound C as claimed in claim 7, is characterized in that: step d) adds additive HOBT or HOAT.

22. application of Compound C as claimed in claim 7, is characterized in that: the acid that step e) is used comprises hydrochloric acid, sulfuric acid and trifluoroacetic acid.

23. application of Compound C as claimed in claim 7, is characterized in that: the alkali that step f) is used comprises triethylamine, DIPEA, pyridine and N-methylmorpholine.

24. application of Compound C as claimed in claim 7, is characterized in that: the condensing agent that step f) is used comprises EDCI, BOP, PyBOP, CDI, HATU, HBTU and DCC.

25. application of Compound C as claimed in claim 7, is characterized in that: step f) adds additive HOBT or HOAT.

26. application of Compound C as claimed in claim 7, is characterized in that: the said alkali of step b) comprises triethylamine, DIPEA, pyridine, N-methylmorpholine, lithium hydroxide, sodium hydroxide and potassium hydroxide.

27. application of Compound C as claimed in claim 7, is characterized in that: step b) strong aqua mass concentration is 28-35%.

28. claim 1-4 are the preparation method of described Compound C arbitrarily, it is characterized in that: in organic solvent, under catalyst action, the compd B of following formula obtains through hydrazine hydrate effect after reacting with tert-Butyl dicarbonate again

Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group.

The preparation method of 29. Compound C as claimed in claim 28, is characterized in that: said catalyzer is DMAP, triethylamine, butyllithium or sodium hydroxide.

The preparation method of 30. Compound C as claimed in claim 28, is characterized in that: compd B, by the compd A of following formula, in organic solvent, under alkali existence condition, reacts and obtains with replacement or unsubstituted benzyl halide

Wherein R is the substituting group of phenyl ring optional position, and R is hydrogen, alkyl or alkoxyl group, and X is chlorine or bromine.

The preparation method of 31. Compound C as claimed in claim 30, is characterized in that: said alkali comprises potassium tert.-butoxide, sodium hydride, potassium hydride KH, two (trimethyl silicon based) Lithamide, two (trimethyl silicon based) sodium amide, two (trimethyl silicon based) potassium amide, lithium diisopropylamine and butyllithium.